Daniella Beckman
About Daniella Beckman
Daniella Beckman, age 46, has served on Vor Biopharma’s board since July 2020; she is currently Chief Financial Officer of Tango Therapeutics and brings deep finance and life sciences experience, including prior interim CFO/consulting roles across early-stage biotech from 2015–2019 . She holds a B.S. in business administration-accounting from Boston University and is designated by Vor’s board as an audit committee financial expert; she is considered independent under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Tango Therapeutics, Inc. | Chief Financial Officer | Sep 2019–present | Public targeted oncology biotech CFO (external executive role) |
| Various early-stage biotech companies | Interim CFO / Consulting | Nov 2015–Sep 2019 | Provided consulting and interim CFO services |
External Roles
| Company | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Blueprint Medicines Corporation | Director | Dec 2021–present | Global precision therapy company; committee roles not disclosed |
| Translate Bio, Inc. (acquired by Sanofi) | Director; Audit Committee member | Oct 2017–Sep 2021 | Served on audit committee until acquisition |
| 5:01 Acquisition Corp (SPAC) | Director | Oct 2020–Oct 2022 | Public SPAC directorship |
Board Governance
- Committee assignments: Audit Committee chair; Compensation Committee member; not on Nominating and Corporate Governance Committee .
- Independence: Board determined Beckman (and all directors other than CEO Robert Ang) are independent under Nasdaq rules .
- Attendance and engagement: Board notes proxy advisor “overboarding” concerns due to her CFO role and multiple boards, but cites her 92% attendance at board/committee meetings since 2022 and significant contributions; in 2024, all directors other than one (not Beckman) attended ≥75% of meetings .
- Board activity and structure: 2024 meetings—Board: 5; Audit: 4; Compensation: 2; Nominating: 0; the Board has an independent chair (Matthew Patterson) and independent directors meet in executive session at least twice a year .
- Risk oversight: Audit Committee oversees financial reporting, cybersecurity/data privacy, risk management, and related person transactions .
Fixed Compensation
| Component | Amount ($) | Notes |
|---|---|---|
| Annual cash retainer | 40,000 | Non-employee director policy |
| Audit Committee member retainer | 7,500 | Policy |
| Audit Committee chair retainer | 15,000 | Policy |
| Compensation Committee member retainer | 5,000 | Policy |
| 2024 fees earned (cash) | 60,000 | Actual cash paid in 2024 |
- The policy totals for Beckman’s roles would sum to $67,500, while actual 2024 cash fees reported were $60,000 (likely reflecting timing/proration) .
Performance Compensation
| Item | 2024 Value/Terms | Vesting/Conditions |
|---|---|---|
| Option awards (fair value) | 34,800 | Per 2024 director compensation table |
| Annual option grant | 30,000 shares | Vests on earlier of 1-year anniversary or next annual meeting; accelerated vesting upon change in control |
| Initial option grant (on appointment) | 60,000 shares | Vests in 36 equal monthly installments; accelerated vesting upon change in control |
- Director equity awards are time-based options; performance metrics are not disclosed for director grants in the policy .
Other Directorships & Interlocks
| Dimension | Details |
|---|---|
| Overboarding signal | Company acknowledges certain proxy advisors may view Beckman as overboarded given CFO role plus multiple boards; Board cites 92% attendance since 2022 and strong engagement as mitigating factors . |
| Shared directorships/conflicts | No related-party transactions disclosed involving Beckman; Audit Committee reviews and approves related person transactions per policy . |
Expertise & Qualifications
- Audit committee financial expert designation, with financial sophistication per Nasdaq requirements; chair of the Audit Committee .
- Extensive finance and public accounting experience in life sciences; CFO of Tango Therapeutics; prior audit committee service at Translate Bio .
Equity Ownership
| Metric | Amount | Date/Context |
|---|---|---|
| Beneficial ownership (shares) | 105,007 | Options exercisable within 60 days of March 1, 2025; represents <1% ownership |
| Ownership percentage | <1% | As of March 1, 2025 |
| Outstanding options (total) | 135,007 | Director outstanding options as of Dec 31, 2024 |
| Hedging/pledging | Prohibited | Insider Trading Policy bans hedging and pledging for directors |
Governance Assessment
- Strengths: Independent director; Audit Committee chair and SEC-designated audit committee financial expert; strong finance background; robust risk oversight including cybersecurity; anti-hedge/pledge policy and Dodd-Frank-compliant clawback policy in place .
- Alignment: Director compensation mix of cash plus time-based options; change-in-control acceleration disclosed; beneficial ownership via options provides at-risk equity exposure, though absolute ownership is below 1% .
- Watch items/RED FLAGS: Potential overboarding risk flagged by proxy advisors due to concurrent CFO role and multiple boards; Board rebuttal cites 92% attendance and strong engagement—monitor time demands and committee workload, especially as Audit chair .
- Conflicts/related-party exposure: No Beckman-specific related-party transactions disclosed; the Audit Committee reviews related-person transactions under a formal policy, reducing conflict risk .